{"entity":{"id":"peter-johnson","kind":"person","name":"Peter Johnson","aka":[],"tldr":"Southampton lymphoma specialist who led the RATHL trial of PET-guided therapy in Hodgkin lymphoma and serves as NHS England's National Clinical Director for Cancer.","summary":"Peter Johnson is Professor of Medical Oncology at the University of Southampton and University Hospital Southampton, working within the Centre for Cancer Immunology, the UK's first dedicated cancer immunology centre. He was chief investigator of the RATHL trial, which established interim PET-CT guided de-escalation of chemotherapy in advanced Hodgkin lymphoma, and his research focuses on antibody and vaccine immunotherapy for lymphoma. He also serves as National Clinical Director for Cancer at NHS England.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.southampton.ac.uk/research/institutes-centres/centre-for-cancer-immunology"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Johnson+PW%5BAuthor%5D+AND+lymphoma"}],"tags":["clinician-scientist","lymphoma","immunotherapy"],"related":[],"cancers":["hodgkin-lymphoma","dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["southampton-cancer"],"pathways":[],"terms":[],"trials":["rathl"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology","institutionId":"southampton-cancer","specialisms":["Lymphoma","Cancer immunotherapy","Medical oncology","Clinical trials"],"profiles":[{"label":"Institution profile","url":"https://www.southampton.ac.uk/research/institutes-centres/centre-for-cancer-immunology"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Johnson+PW%5BAuthor%5D+AND+lymphoma"}],"papers":[{"title":"Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma","journal":"New England Journal of Medicine","year":2016,"url":"https://doi.org/10.1056/NEJMoa1510093","doi":"10.1056/NEJMoa1510093"}],"orcid":"0000-0003-2306-4974"},"route":"/people/peter-johnson/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"institution":[{"id":"southampton-cancer","kind":"institution","name":"University Hospital Southampton / Centre for Cancer Immunology","route":"/institutions/southampton-cancer/"}],"trial":[{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/"},{"id":"rathl","kind":"trial","name":"RATHL","route":"/trials/rathl/"}],"paper":[{"id":"paper-nhs-galleri-performance-nat-med-2026","kind":"paper","name":"Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial","route":"/key-papers/paper-nhs-galleri-performance-nat-med-2026/"},{"id":"paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019","kind":"paper","name":"Randomized phase III trial of ibrutinib and R-CHOP in non-germinal centre B-cell diffuse large B-cell lymphoma (PHOENIX)","route":"/key-papers/paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019/"}]}}